Search company, investor...
Bird Rock Bio company logo

Bird Rock Bio

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$8M | 3 yrs ago

About Bird Rock Bio

Bird Rock Bio, formerly RuiYi, is a clinical stage biopharmaceutical company focused on developing immuno-inflammatory regulators. The company's strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best in class therapeutic antibodies with significant clinical and commercial differentiation.

Headquarters Location

2223 Avenida de la Playa Suite 205

La Jolla, California, 92037,

United States


Missing: Bird Rock Bio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bird Rock Bio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bird Rock Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bird Rock Bio is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Bird Rock Bio Patents

Bird Rock Bio has filed 4 patents.

The 3 most popular patent topics include:

  • CB1 receptor antagonists
  • Cannabinoids
  • Designer drugs
patents chart

Application Date

Grant Date


Related Topics




Cannabinoids, Designer drugs, Naphthoylindoles, CB1 receptor antagonists, JWH cannabinoids


Application Date


Grant Date



Related Topics

Cannabinoids, Designer drugs, Naphthoylindoles, CB1 receptor antagonists, JWH cannabinoids



Latest Bird Rock Bio News

Bird Rock Bio files IND application for phase 2 study of Nimacimab for treatment of renal diseases

May 29, 2020

X Bird Rock Bio has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a phase 2 clinical study of nimacimab, also known as RYI-018, in patients with one of the following renal diseases: diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), or immunoglobulin A (IgA) nephropathy. (Credit: The U.S. Food and Drug Administration) Subscribe to our email newsletter Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 (CB1) receptor, which has a known association in renal fibrosis and inflammation. Bird Rock Bio owns the worldwide rights to nimacimab, with patents issued in the U.S. and other territories, including claims to cannabinoid 1 receptor antibodies with inverse agonist function. The safety and tolerability assessments from the completed phase 1b study in patients with diabetes or prediabetes demonstrated no serious adverse events (SAEs), no early terminations of treatment due to adverse events, and no adverse events of concern occurring in a dose-dependent manner. The pharmacokinetic assessment showed a half-life of approximately three weeks, potentially allowing for monthly dosing. Some encouraging trends were observed in the exploratory biomarkers after the three-week dosing period. “We are looking forward to the evaluation of nimacimab as a potential treatment for renal diseases with significant unmet need,” said Paul Grayson, the Company’s President and CEO. “Preclinical data suggest that CB1 antagonism with nimacimab may significantly improve renal function and has the potential to provide a first-in-class treatment option in several indications.” In parallel to carrying out the clinical trial, the Company has successfully completed drug manufacturing at a 1,000-liter scale, demonstrated stability of the drug product in pre-filled syringes for more than 12 months and has completed a 26-week toxicology study with no significant findings. “The filling of this IND represents the culmination of multiple preparatory activities that position nimacimab for a large value inflection as the Company pursues strategic options for the conduct of the study,” said Alyssa Lochbaum, CFO, Bird Rock Bio. Source: Company Press Release

Bird Rock Bio Frequently Asked Questions (FAQ)

  • When was Bird Rock Bio founded?

    Bird Rock Bio was founded in 2008.

  • Where is Bird Rock Bio's headquarters?

    Bird Rock Bio's headquarters is located at 2223 Avenida de la Playa, La Jolla.

  • What is Bird Rock Bio's latest funding round?

    Bird Rock Bio's latest funding round is Unattributed VC.

  • How much did Bird Rock Bio raise?

    Bird Rock Bio raised a total of $80.5M.

  • Who are the investors of Bird Rock Bio?

    Investors of Bird Rock Bio include Versant Ventures, Samsara BioCapital, 5AM Ventures, Apposite Capital, M Ventures and 5 more.

  • Who are Bird Rock Bio's competitors?

    Competitors of Bird Rock Bio include Aphios, Catalyst Biosciences, Oligomerix, AM-Pharma, PhaseBio Pharmaceuticals and 13 more.

Compare Bird Rock Bio to Competitors

Aphios Logo

Aphios is a clinical stage biotechnology company. It develops technology platfroms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, the company develops therapeutics to prevent disease, maintain health, and treat chronic diseases, including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19. The company was founded in 2018 and is based in Woburn, Massachusetts.


TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging


AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.


Glycotope is a biopharmaceutical company in glycomics and its application for development of biopharmaceuticals.

Acureon Pharmaceuticals

ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.